Stock A006280 GC BIOPHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

GC Biopharma Corp. Stock

Equities

A006280

KR7006280002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
112,000 KRW 0.00% Intraday chart for GC Biopharma Corp. +1.73% -10.76%
Mar. 20 GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI) CI

Financials

Sales 2024 * 1,744B 1.27B Sales 2025 * 1,855B 1.35B Capitalization 1,278B 931M
Net income 2024 * 29B 21.11M Net income 2025 * 48B 34.94M EV / Sales 2024 * 1.09 x
Net Debt 2024 * 617B 449M Net Debt 2025 * 562B 409M EV / Sales 2025 * 0.99 x
P/E ratio 2024 *
44.7 x
P/E ratio 2025 *
26.9 x
Employees 2,098
Yield 2024 *
1.53%
Yield 2025 *
1.53%
Free-Float 46.21%
More Fundamentals * Assessed data

Chart GC Biopharma Corp.

Dynamic Chart

Latest news about GC Biopharma Corp.

GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI) CI
GC Biopharma Establishes mRNA Production Facility in Hwasun, Korea CI
GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GC Biopharma Applies for MFDS Approval CI
Immetas Therapeutics and GC Biopharma Announces Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases CI
GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Green Cross's Net Income Plunges in Q2 MT
GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt CI
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia CI
GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Green Cross Swings to Loss in Q1 MT
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates MT
GC Biopharma Receives WHO Pre-Qualification for BARYCELA CI
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea CI
More news

Press releases GC Biopharma Corp.

GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent PU
Green Cross : Curevo Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines PU
Green Cross : GC Pharma Reports Q1 2020 Results AQ
Green Cross : GC Pharma Reports Full Year 2019 Results AQ
More press releases

News in other languages on GC Biopharma Corp.

Gorbaciov : morto a 91 anni l'ultimo leader dell'Urss (milanofinanza.it)
El Kospi de Corea cae un 1% y amplía sus pérdidas por tercer día -- Market Talk
MÄRKTE ASIEN/Aktien mehrheitlich im Plus - Seoul von Technikwerten gedrückt
Grifols S A : cierra la adquisición de varias plantas en Canadá por 370 millones de dólares
Grifols achète des actifs de plasma à Green Cross pour 460 M$
More news

Quotes and Performance

1 week+1.73%
Current month-7.67%
1 month-9.97%
3 months+0.72%
6 months+18.39%
Current year-10.76%
More quotes

Highs and lows

1 week
108 600.00
Extreme 108600
112 800.00
1 month
108 600.00
Extreme 108600
125 800.00
Current year
107 600.00
Extreme 107600
127 800.00
1 year
93 000.00
Extreme 93000
134 300.00
3 years
93 000.00
Extreme 93000
403 000.00
5 years
93 000.00
Extreme 93000
538 000.00
10 years
93 000.00
Extreme 93000
538 000.00
More quotes

Managers and Directors - GC Biopharma Corp.

Managers TitleAgeSince
Eun-Cheol Huh CEO
 Chief Executive Officer 52 05-12-31
Ok-Gyu Go CMP
 Compliance Officer - 13-12-31
In-Jae Lee BRD
 Director/Board Member 61 -
Members of the board TitleAgeSince
Il-Sup Huh PRN
 Corporate Officer/Principal 69 -
Eun-Cheol Huh CEO
 Chief Executive Officer 52 05-12-31
Byeong-Hwa Kim BRD
 Director/Board Member 65 -
More insiders

ETFs positioned on GC Biopharma Corp.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.38% 2 M€ -14.14%
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.05% 2 M€ -.--%
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
More ETFs positioned on GC Biopharma Corp.

Quotes

Date Price Change Volume
24-04-22 112,000 0.00% 8 871
24-04-22 112,000 +2.66% 9,580
24-04-19 109,100 -1.36% 17,030
24-04-18 110,600 +0.91% 10,125
24-04-17 109,600 -0.36% 14,914

End-of-day quote Korea S.E., April 22, 2024

More quotes

Company Profile

Green Cross Corp is a Korea-based company that mainly engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures pharmaceutical products including blood products, general products, vaccines, over the counter (OTC) drugs, diagnostic reagents, placental injections, cell therapies, vaccine fertilized eggs and blood diagnostic products, among others. The Company also provides genome analysis services.
Sector
Pharmaceuticals
Calendar
2024-05-12 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for GC Biopharma Corp.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
112,000 KRW
Average target price
144,667 KRW
Spread / Average Target
+29.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GC BIOPHARMA CORP. Stock GC Biopharma Corp.
-10.76% 927M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.92% 659B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.68% 557B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.59% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.38% 322B
ABBVIE INC. Stock AbbVie Inc.
+9.39% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.30% 215B
NOVARTIS AG Stock Novartis AG
+4.80% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.05% 200B
PFIZER, INC. Stock Pfizer, Inc.
-8.58% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A006280 Stock